

TRADEMARK ASSIGNMENT COVER SHEET

Electronic Version v1.1
Stylesheet Version v1.2

ETAS ID: TM853254

SUBMISSION TYPE:	NEW ASSIGNMENT		
NATURE OF CONVEYANCE:	SECURITY INTEREST		
CONVEYING PARTY DATA			
Name	Formerly	Execution Date	Entity Type
Taysha Gene Therapies, Inc.		11/13/2023	Corporation: DELAWARE
RECEIVING PARTY DATA			
Name:	Trinity Capital Inc.		
Street Address:	1 N 1st Street, Floor 3		
City:	Phoenix		
State/Country:	ARIZONA		
Postal Code:	85004		
Entity Type:	Corporation: MARYLAND		
PROPERTY NUMBERS Total: 1			
Property Type	Number	Word Mark	
Serial Number:	90773805	TAYSHA GENE THERAPIES	
CORRESPONDENCE DATA			
Fax Number:			
<i>Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.</i>			
Phone:	8004945225		
Email:	ipteam@cogencyglobal.com		
Correspondent Name:	JAY DASILVA		
Address Line 1:	1025 CONNECTICUT AVE., NW, STE. 712		
Address Line 2:	COGENCY GLOBAL INC.		
Address Line 4:	WASHINGTON, D.C. 20036		
ATTORNEY DOCKET NUMBER:	2177290 TM		
NAME OF SUBMITTER:	Yvette Stohler		
SIGNATURE:	/Yvette Stohler/		
DATE SIGNED:	11/14/2023		
Total Attachments: 19			
source=Trinity-Taysha IPSA#page1.tif			
source=Trinity-Taysha IPSA#page2.tif			
source=Trinity-Taysha IPSA#page3.tif			
source=Trinity-Taysha IPSA#page4.tif			

OP \$40.00 90773805

source=Trinity-Taysha IPSA#page5.tif
source=Trinity-Taysha IPSA#page6.tif
source=Trinity-Taysha IPSA#page7.tif
source=Trinity-Taysha IPSA#page8.tif
source=Trinity-Taysha IPSA#page9.tif
source=Trinity-Taysha IPSA#page10.tif
source=Trinity-Taysha IPSA#page11.tif
source=Trinity-Taysha IPSA#page12.tif
source=Trinity-Taysha IPSA#page13.tif
source=Trinity-Taysha IPSA#page14.tif
source=Trinity-Taysha IPSA#page15.tif
source=Trinity-Taysha IPSA#page16.tif
source=Trinity-Taysha IPSA#page17.tif
source=Trinity-Taysha IPSA#page18.tif
source=Trinity-Taysha IPSA#page19.tif

INTELLECTUAL PROPERTY SECURITY AGREEMENT

THIS INTELLECTUAL PROPERTY SECURITY AGREEMENT ("Agreement") dated as of November 13, 2023, is made by TAYSHA GENE THERAPIES, INC., a Delaware corporation (the "Grantor"), in favor of TRINITY CAPITAL INC., a Maryland corporation, as administrative agent and collateral agent for the Lenders ("Administrative Agent").

RECITALS

A. Grantor has entered into a Loan and Security Agreement with the lenders party thereto and the Administrative Agent, dated as of the date hereof (as amended, restated, or otherwise modified from time to time, the "Loan Agreement"). All capitalized terms used but not defined herein shall have the respective meanings given to them in the Loan Agreement.

B. Pursuant to the terms of the Loan Agreement, Grantor has granted to Administrative Agent, for the benefit of the Lenders, a security interest in all of Grantor's right, title and interest, whether presently existing or hereafter acquired, in, to and under all of the Collateral.

NOW, THEREFORE, for good and valuable consideration, receipt of which is hereby acknowledged, and intending to be legally bound, as collateral security for the prompt and complete payment when due of its obligations under the Loan Agreement, Grantor hereby represents, warrants, covenants and agrees as follows:

AGREEMENT

1. Grant of Security Interest. To secure its obligations under the Loan Agreement, Grantor grants and pledges to Administrative Agent, for the benefit of the Lenders, a security interest in all of Grantor's right, title and interest in, to and under Grantor's intellectual property to the extent constituting Collateral (all of which shall collectively be called the "Intellectual Property Collateral"), including, without limitation, the following:

(a) Any and all copyright rights, copyright applications, copyright registrations and like protections in each work of authorship and derivative work thereof, whether published or unpublished and whether or not the same also constitutes a trade secret, now or hereafter existing, created, acquired or held, including without limitation those set forth on Exhibit A attached hereto (collectively, the "Copyrights");

(b) Any and all trade secrets, and any and all intellectual property rights in computer software and computer software products now or hereafter existing, created, acquired or held;

(c) Any and all design rights that may be available to Grantor now or hereafter existing, created, acquired or held;

(d) All patents, patent applications and like protections including, without limitation, improvements, divisions, continuations, renewals, reissues, extensions, re-examination certificates, utility models, and continuations-in-part of the same, including without limitation the patents and patent applications set forth on Exhibit B attached hereto (collectively, the "Patents");

(e) Any trademark and servicemark rights, whether registered or not, applications to register and registrations of the same and like protections, and the entire goodwill of the business of Grantor connected with and symbolized by such trademarks, including without limitation those set forth on Exhibit C attached hereto (collectively, the "Trademarks");

(f) All mask works or similar rights available for the protection of semiconductor chips, now owned or hereafter acquired, including, without limitation those set forth on Exhibit D attached hereto (collectively, the "Mask Works");

(g) Any and all claims for damages by way of past, present and future infringements of any of the rights included above, with the right, but not the obligation, to sue for and collect such damages for said use or infringement of the intellectual property rights identified above;

(h) All licenses or other rights to use any of the Copyrights, Patents, Trademarks, or Mask Works and all license fees and royalties arising from such use to the extent permitted by such license or rights;

(i) All amendments, renewals and extensions of any of the Copyrights, Trademarks, Patents, or Mask Works; and

(j) All proceeds and products of the foregoing, including without limitation all payments under insurance or any indemnity or warranty payable in respect of any of the foregoing.

2. Recordation. Grantor authorizes the Commissioner for Patents, the Commissioner for Trademarks and the Register of Copyrights and any other government officials to record and register this Agreement upon request by Administrative Agent.

Grantor hereby authorizes Administrative Agent to (a) modify this Agreement unilaterally by amending the exhibits to this Agreement to include any Intellectual Property Collateral which Grantor obtains subsequent to the date of this Agreement and (b) file a duplicate original of this Agreement containing amended exhibits reflecting such new Intellectual Property Collateral.

3. Loan Documents. This Agreement has been entered into pursuant to and in conjunction with the Loan Agreement, which is hereby incorporated by reference. The provisions of the Loan Agreement shall supersede and control over any conflicting or inconsistent provision herein. The rights and remedies of Lender with respect to the Intellectual Property Collateral are as provided by the Loan Agreement and related documents, and nothing in this Agreement shall be deemed to limit such rights and remedies.

4. Execution in Counterparts. This Agreement and any amendments, waivers, consents or supplements hereto may be executed in any number of counterparts, and by different parties hereto in separate counterparts, each of which when so delivered shall be deemed an original, but all of which counterparts shall constitute but one and the same instrument. Delivery of an executed counterpart of a signature page of this Agreement by facsimile, portable document format (.pdf) or other electronic transmission will be as effective as delivery of a manually executed counterpart hereof.

5. Successors and Assigns. The provisions of this Agreement shall inure to the benefit of the parties hereto and their respective successors and assigns. Grantor shall not assign its obligations under this Agreement without Administrative Agent's express prior written consent, and any such attempted assignment shall be void and of no effect. Administrative Agent may assign, transfer, or endorse its rights hereunder pursuant to the terms of the Loan Agreement, and all of such rights shall inure to the benefit of Administrative Agent's successors and assigns.

6. Governing Law. This Agreement has been negotiated and delivered to Administrative Agent in the State of California, and shall have been accepted by Administrative Agent in the State of California. This Agreement shall be governed by, and construed and enforced in accordance with, the laws of the State of California, excluding conflict of laws principles that would cause the application of laws of any other jurisdiction.

[Balance of Page Intentionally Left Blank.]

IN WITNESS WHEREOF, the parties have caused this Intellectual Property Security Agreement to be duly executed as of the day and year first above written.

GRANTOR:

TAYSHA GENE THERAPIES, INC., a Delaware corporation

DocuSigned by:
By: Kamran Alam
Name: Kamran Alam
Title: Chief Financial Officer

LENDER:

TRINITY CAPITAL INC.,
a Maryland corporation, as Administrative Agent

DocuSigned by:
By: Sarah Stanton
Name: Sarah Stanton
Title: General Counsel and Chief Compliance Officer

COPY VIEW

EXHIBIT A

COPYRIGHTS

None.

COPY VIEW

EXHIBIT B

PATENTS

See attached.

COPY VIEW

Cooley Docket No.	Title/Mark	Application No.	Reg. No.	Case Status	Country
TAYS-001 – Transgene: SLC6A1 – Indication: SLC6A1 Haploinsufficiency Disorder (TSHA-103)					
Assignee: The Board of Regents of the University of Texas System					
TAYS-001/P01US	TRANSGENE CASSETTES DESIGNED TO EXPRESS AE HUMAN CODON-OPTIMIZED GENE SLC6A1	62/932,824 11/8/2019		Expired	United States of America
TAYS-001/001WO	TRANSGENE CASSETTES DESIGNED TO EXPRESS AE HUMAN CODON-OPTIMIZED GENE SLC6A1	PCT/US2020/059576 11/7/2020		Expired/PCT Period Over	Patent Cooperation Treaty
TAYS-001/001US	TRANSGENE CASSETTES, AAV VECTORS AND AAV VIRAL VECTORS FOR THE EXPRESSION OF HUMAN CODON-OPTIMIZED SLC6A1	17/092,240 11/7/2020		Pending	United States of America
TAYS-001/N01EP	TRANSGENE CASSETTES DESIGNED TO EXPRESS AE HUMAN CODON-OPTIMIZED GENE SLC6A1	20884323.5 11/7/2020		Pending	European Patent Office
TAYS-002 – Transgene: SURF1 – Indication: SURF1-Associated Leigh Syndrome (TSHA-104)					
Assignee: The Board of Regents of the University of Texas System					
TAYS-002/P01US	TRANSGENE CASSETTES DESIGNED TO EXPRESS THE HUMAN CODON-OPTIMIZED GENE SURF1	62/932,828 11/8/2019		Expired	United States of America
TAYS-002/001WO	RECOMBINANT ADENO-ASSOCIATED VIRAL VECTOR FOR GENE DELIVERY	PCT/US2020/059576 11/7/2020		Expired/PCT Period Over	Patent Cooperation Treaty
TAYS-002/001US	RECOMBINANT ADENO-ASSOCIATED VIRAL VECTOR FOR GENE DELIVERY	17/092,239 11/7/2020		Pending	United States of America
TAYS-002/N01EP	RECOMBINANT ADENO-ASSOCIATED VIRAL VECTOR FOR GENE DELIVERY	20885638.5 11/7/2020		Pending	European Patent Office
TAYS-003 – Transgene: MECP2 – Indication: Rett Syndrome (TSHA-102)					
Assignee: The Board of Regents of the University of Texas System					
TAYS-003/P01US	TRANSGENE CASSETTES DESIGNED TO EXPRESS A HUMAN CODON-OPTIMIZED GENE MECP2	62/944,209 12/5/2019		Expired	United States of America
TAYS-003/P02US	TRANSGENE CASSETTES DESIGNED TO EXPRESS A HUMAN MECP2	62/946,696 12/11/2019		Expired	United States of America
TAYS-003/P03US	TRANSGENE CASSETTES DESIGNED TO EXPRESS A HUMAN MECP2 GENE	63/008,159 4/10/2020		Expired	United States of America
TAYS-003/P04US	TRANSGENE CASSETTES DESIGNED TO EXPRESS A HUMAN MECP2 GENE	63/047,596 7/2/2020		Expired	United States of America
TAYS-003/001WO	TRANSGENE CASSETTES DESIGNED TO EXPRESS A HUMAN MECP2 GENE	PCT/US2020/063300 12/4/2020		Expired/PCT Period Over	Patent Cooperation Treaty
TAYS-003/001US	TRANSGENE CASSETTES DESIGNED TO EXPRESS A HUMAN MECP2 GENE	17/112,299 12/4/2020		Allowed	United States of America
TAYS-003/N01EP	TRANSGENE CASSETTES DESIGNED TO EXPRESS A HUMAN MECP2 GENE	20895053.5 12/4/2020		Pending	European Patent Office
TAYS-003/N01HK	TRANSGENE CASSETTES DESIGNED TO EXPRESS A HUMAN MECP2 GENE	62023071325.2 12/4/2020		Pending	Hong Kong
TAYS-003/N01IL	TRANSGENE CASSETTES DESIGNED TO EXPRESS A HUMAN MECP2 GENE	293431 12/4/2020		Pending	Israel

TAYS-003/N01JP	TRANSGENE CASSETTES DESIGNED TO EXPRESS A HUMAN MECP2 GENE	2022-534148 12/4/2020		Pending	Japan
TAYS-004 – Transgene: <i>Anti-LBE34 RNAI</i> – Indication: <i>Angelman Syndrome (TSHA-106)</i> Assignee: The Board of Regents of the University of Texas System					
TAYS-004/P01US	GENE THERAPY FOR ANGELMAN SYNDROME	62/969,580 2/3/2020		Abandoned	United States of America
TAYS-004/P02US	GENE THERAPY FOR ANGELMAN SYNDROME	62/970,890 2/6/2020		Abandoned	United States of America
TAYS-004/P03US	GENE THERAPY FOR ANGELMAN SYNDROME	63/145,123 2/3/2021		Expired	United States of America
TAYS-004/P04US	GENE THERAPY FOR ANGELMAN SYNDROME	63/221,682 7/14/2021		Expired	United States of America
TAYS-004/001WO	GENE THERAPY FOR ANGELMAN SYNDROME	PCT/US2022/014926 2/2/2022		Expired/PCT Pending Over	United States of America International Cooperation Treaty
TAYS-004/N01EP	GENE THERAPY FOR ANGELMAN SYNDROME	22705645.4 2/2/2022		Pending	European Patent Office
TAYS-004/N01US	GENE THERAPY FOR ANGELMAN SYNDROME	18/274,485 2/2/2022		Pending	United States of America
TAYS-005 – Transgene: <i>GBE</i> – Indication: <i>Adult polyglucosan body disease (TSHA-112), Glycogen Storage Disease (TSHA-115)</i> Assignee: The Board of Regents of the University of Texas System					
TAYS-005/P01US	TRANSGENE CASSETTES DESIGNED TO EXPRESS THE HUMAN CODON-OPTIMIZED GENE GBE	62/979,734 2/21/2020		Abandoned	United States of America
TAYS-005/P02US	TRANSGENE CASSETTES DESIGNED TO EXPRESS THE HUMAN CODON-OPTIMIZED GENE GBE	63/159,694 3/11/2021		Abandoned	United States of America
TAYS-006 – Transgene: <i>EPM24</i> or <i>NHLRC1</i> – Indication: <i>Lathyrus Disease (TSHA-111)</i> Assignee: The Board of Regents of the University of Texas System					
TAYS-006/P01US	TRANSGENE CASSETTES DESIGNED TO EXPRESS THE HUMAN CODON-OPTIMIZED GENE EPM24 OR NHLRC1	62/979,774 2/21/2020		Abandoned	United States of America
TAYS-006/P02US	TRANSGENE CASSETTES DESIGNED TO EXPRESS THE HUMAN CODON-OPTIMIZED GENE EPM24 OR NHLRC1	63/159,697 3/11/2021		Abandoned	United States of America
TAYS-006/P03US	TRANSGENE CASSETTES DESIGNED TO EXPRESS THE HUMAN CODON-OPTIMIZED GENE EPM24 OR NHLRC1	63/317,329 3/7/2022		Abandoned	United States of America
TAYS-007 – Transgene: <i>KCTD7</i> – Indication: <i>progressive myoclonic epilepsy</i> Assignee: The Board of Regents of the University of Texas System					
TAYS-007/P01US	GENE REPLACEMENT THERAPY FOR KCTD7	62/979,761 2/21/2020		Abandoned	United States of America
TAYS-007/P02US	GENE REPLACEMENT THERAPY FOR KCTD7	63/159,698 3/11/2021		Abandoned	United States of America
TAYS-008 – Transgene: <i>MECP2</i> – Indication: <i>Rett Syndrome (TSHA-102)</i> Assignees: The University Court of the University of Edinburgh and The University Court of the University of Glasgow					

TAYS-009/N01WO	MECP2 EXPRESSION CASSETTES	GB 1704704.4				Great Britain
TAYS-008/001WO	MECP2 BASED THERAPY	GB 1704722.6				Great Britain
TAYS-008/N01BR	MECP2 BASED THERAPY	PCT/GB2018/050772		Expired/PCT Period Over		Patent Cooperation Treaty
TAYS-008/N01BR	MECP2 BASED THERAPY	112019019833-4		Pending		Brazil
TAYS-008/N01CA	MECP2 BASED THERAPY	3057425		Pending		Canada
TAYS-008/N01CN	MECP2 BASED THERAPY	201880034073.9		Pending		China
TAYS-008/N01JP	MECP2 BASED THERAPY	2019-552111	7170656	Registered	11/4/2022	Japan
TAYS-008/N01US	MECP2 BASED THERAPY	16/497.271		Pending		United States of America
TAYS-009 – Transgene: MECP2 – Indication: Rett Syndrome (TSHA-102)						
Assignees: The University Court of the University of Edinburgh and The University Court of the University of Glasgow						
	MECP2 EXPRESSION CASSETTES	GB 1704704.4				Great Britain
	MECP2 BASED THERAPY	GB 1704722.6				Great Britain
TAYS-009/001WO	MECP2 EXPRESSION CASSETTES	PCT/GB2018/050772		Expired/PCT Period Over		Patent Cooperation Treaty
TAYS-009/N01AU	MECP2 EXPRESSION CASSETTES	2018239498	2018239498	Registered	6/23/2022	Australia
TAYS-009/N01BR	MECP2 EXPRESSION CASSETTES	12019019857-1		Pending		Brazil
TAYS-009/N01CA	MECP2 EXPRESSION CASSETTES	3057430		Pending		Canada
TAYS-009/N01CN	MECP2 EXPRESSION CASSETTES	201880034077.7		Pending		China
TAYS-009/N01EP	MECP2 EXPRESSION CASSETTES	18715097.4		Pending		European Patent Office
TAYS-009/N01IN	MECP2 EXPRESSION CASSETTES	201917042741		Pending		India
TAYS-009/N01JP	MECP2 EXPRESSION CASSETTES	2019-552125		Abandoned		Japan
TAYS-009/D01JP	MECP2 EXPRESSION CASSETTES	2022-177514		Pending		Japan
TAYS-009/N01KR	MECP2 EXPRESSION CASSETTES	10-2019-7031342		Pending		Republic of Korea
TAYS-009/N01RU	MECP2 EXPRESSION CASSETTES	2019/133002		Abandoned		Russian Federation

TAYS-009/N01US	MECP2 EXPRESSION CASSETTES	16/497,277 3/23/2018		Allowed	United States of America
TAYS-010 – Transgene: G4N – Indication: Giant Axonal Neuropathy (TSHA-120)					
Assignee: The Board of Regents of the University of Texas System					
TAYS-010/P01US	COMPOSITIONS AND METHODS FOR TREATMENT OF NEUROLOGICAL DISORDERS	63/010,179 4/15/2020		Expired	United States of America
TAYS-010/001US	COMPOSITIONS AND METHODS FOR TREATMENT OF NEUROLOGICAL DISORDERS	17/230,484 4/14/2021	11,753,655 9/12/2023	Registered	United States of America
TAYS-010/C01US	COMPOSITIONS AND METHODS FOR TREATMENT OF NEUROLOGICAL DISORDERS	18/355,380 7/19/2023		Pending	United States of America
TAYS-010/001WO	COMPOSITIONS AND METHODS FOR TREATMENT OF NEUROLOGICAL DISORDERS	PCT/US2021/027266 4/14/2021		Expired/PT Period Over	Patent Cooperation Treaty Australia
TAYS-010/N01AU	COMPOSITIONS AND METHODS FOR TREATMENT OF NEUROLOGICAL DISORDERS	2021,255,934 4/14/2021		Pending	Canada
TAYS-010/N01CA	COMPOSITIONS AND METHODS FOR TREATMENT OF NEUROLOGICAL DISORDERS	3175406 4/14/2021		Pending	China
TAYS-010/N01CN	COMPOSITIONS AND METHODS FOR TREATMENT OF NEUROLOGICAL DISORDERS	202180042428.0 4/14/2021		Pending	European Patent Office
TAYS-010/N01EP	COMPOSITIONS AND METHODS FOR TREATMENT OF NEUROLOGICAL DISORDERS	21789434.4 4/14/2021		Pending	Hong Kong
TAYS-010/N01HK	COMPOSITIONS AND METHODS FOR TREATMENT OF NEUROLOGICAL DISORDERS	62023075588.7 4/14/2021		Pending	Israel
TAYS-010/N01IL	COMPOSITIONS AND METHODS FOR TREATMENT OF NEUROLOGICAL DISORDERS	296857 4/14/2021		Pending	Japan
TAYS-010/N01JP	COMPOSITIONS AND METHODS FOR TREATMENT OF NEUROLOGICAL DISORDERS	2022-562939 4/14/2021		Pending	Republic of Korea
TAYS-010/N01KR	COMPOSITIONS AND METHODS FOR TREATMENT OF NEUROLOGICAL DISORDERS	9-2022-7039686 4/14/2021		Pending	Singapore
TAYS-010/N01SG	COMPOSITIONS AND METHODS FOR TREATMENT OF NEUROLOGICAL DISORDERS	11202253658P 4/14/2021		Pending	
TAYS-011 – Transgene: CLN1 – Indication: CLN1 Disease/familial Batten Disease (TSHA-118)					
Assignee: The University of North Carolina at Chapel Hill					
TAYS-011/000US	OPTIMIZED CLN1 GENES AND EXPRESSION CASSETTES AND THEIR USE	62/349,411 6/13/2016		Expired	United States of America
TAYS-011/01WO	OPTIMIZED CLN1 GENES AND EXPRESSION CASSETTES AND THEIR USE	PCT/US2017/037118 6/13/2017		Expired/PCT Period Over	Patent Cooperation Treaty Australia
TAYS-011/01AU	OPTIMIZED CLN1 GENES AND EXPRESSION CASSETTES AND THEIR USE	2017284198 6/13/2017		Pending	Brazil
TAYS-011/01BR	OPTIMIZED CLN1 GENES AND EXPRESSION CASSETTES AND THEIR USE	BR112018075692 6/13/2017		Pending	Canada
TAYS-011/01CA	OPTIMIZED CLN1 GENES AND EXPRESSION CASSETTES AND THEIR USE	3024536 6/13/2017		Abandoned	China
TAYS-011/01CN	OPTIMIZED CLN1 GENES AND EXPRESSION CASSETTES AND THEIR USE	201780036781.1 6/13/2017		Abandoned	

TAYS-011/01EP	OPTIMIZED CLNI GENES AND EXPRESSION CASSETTES AND THEIR USE	17813890.5	6/13/2017		Pending	European Patent Office
TAYS-011/01HK	OPTIMIZED CLNI GENES AND EXPRESSION CASSETTES AND THEIR USE	19131040.8	6/13/2017		Pending	Hong Kong
TAYS-011/01IL	OPTIMIZED CLNI GENES AND EXPRESSION CASSETTES AND THEIR USE	263009	6/13/2017	263009	Registered	Israel
TAYS-011/01IN	OPTIMIZED CLNI GENES AND EXPRESSION CASSETTES AND THEIR USE	201947000627	6/13/2017		Pending	India
TAYS-011/01JP	OPTIMIZED CLNI GENES AND EXPRESSION CASSETTES AND THEIR USE	2018-564943	6/13/2017		Abandoned	Japan
TAYS-011/01KR	OPTIMIZED CLNI GENES AND EXPRESSION CASSETTES AND THEIR USE	10-2018-7035890	6/13/2017		Pending	Republic of Korea
TAYS-011/01MX	OPTIMIZED CLNI GENES AND EXPRESSION CASSETTES AND THEIR USE	MX/a/2018/015461	6/13/2017		Abandoned	Mexico
TAYS-011/01NZ	OPTIMIZED CLNI GENES AND EXPRESSION CASSETTES AND THEIR USE	748505	6/13/2017		Abandoned	New Zealand
TAYS-011/01RU	OPTIMIZED CLNI GENES AND EXPRESSION CASSETTES AND THEIR USE	2018145010	6/13/2017		Abandoned	Russian Federation
TAYS-011/01US	OPTIMIZED CLNI GENES AND EXPRESSION CASSETTES AND THEIR USE	16305.337	6/13/2017	1504.435	Registered	United States of America
TAYS-011/01US	OPTIMIZED CLNI GENES AND EXPRESSION CASSETTES AND THEIR USE	18/052,082	11/2/2022		Pending	United States of America
TAYS-011/01ZA	OPTIMIZED CLNI GENES AND EXPRESSION CASSETTES AND THEIR USE	2018/07817	6/13/2017		Pending	South Africa
TAYS-012 - Transgene: Regulatory miRNA sequences for <i>MECP2</i> - Identification: Rett Syndrome (TSHA-102)						
Assignee: The University of North Carolina at Chapel Hill						
TAYS-012/P01US	FEEDBACK ENABLED SYNTHETIC GENES, TARGET SEED MATCH CASSETTES, AND THEIR USES	2725,126	8/30/2018		Expired	United States of America
TAYS-012/P02US	FEEDBACK ENABLED SYNTHETIC GENES, TARGET SEED MATCH CASSETTES, AND THEIR USES	62/861,044	6/13/2019		Expired	United States of America
TAYS-012/02WO	FEEDBACK ENABLED SYNTHETIC GENES, TARGET SEED MATCH CASSETTES, AND THEIR USES	PCT/US2019/048776	8/29/2019		Expired/PCT Period Over	Patent Cooperation Treaty
TAYS-012/02AU	FEEDBACK ENABLED SYNTHETIC GENES, TARGET SEED MATCH CASSETTES, AND THEIR USES	2019333140	8/29/2019		Pending	Australia
TAYS-012/02BR	FEEDBACK ENABLED SYNTHETIC GENES, TARGET SEED MATCH CASSETTES, AND THEIR USES	BR112021003469-2	8/29/2019		Abandoned	Brazil
TAYS-012/02CA	FEEDBACK ENABLED SYNTHETIC GENES, TARGET SEED MATCH CASSETTES, AND THEIR USES	3110289	8/29/2019		Abandoned	Canada

TAYYS-012/02CN	FEEDBACK ENABLED SYNTHETIC GENES, TARGET SEED MATCH CASSETTES, AND THEIR USES	201980070905.7 8/29/2019		Pending	China
TAYYS-012/02EP	FEEDBACK ENABLED SYNTHETIC GENES, TARGET SEED MATCH CASSETTES, AND THEIR USES	19853521.3 8/29/2019		Pending	European Patent Office
TAYYS-012/02HK	FEEDBACK ENABLED SYNTHETIC GENES, TARGET SEED MATCH CASSETTES, AND THEIR USES	62021042632.1 8/29/2019		Pending	Hong Kong
TAYYS-012/02IL	FEEDBACK ENABLED SYNTHETIC GENES, TARGET SEED MATCH CASSETTES, AND THEIR USES	280956 8/29/2019		Pending	Israel
TAYYS-012/02IN	FEEDBACK ENABLED SYNTHETIC GENES, TARGET SEED MATCH CASSETTES, AND THEIR USES	202117009021 8/29/2019		Abandoned	India
TAYYS-012/02JP	FEEDBACK ENABLED SYNTHETIC GENES, TARGET SEED MATCH CASSETTES, AND THEIR USES	2021-501432 8/29/2019		Pending	Japan
TAYYS-012/02KR	FEEDBACK ENABLED SYNTHETIC GENES, TARGET SEED MATCH CASSETTES, AND THEIR USES	10-2021-7008991 8/29/2019		Pending	Republic of Korea
TAYYS-012/02MX	FEEDBACK ENABLED SYNTHETIC GENES, TARGET SEED MATCH CASSETTES, AND THEIR USES	MX/A/2021/083418 8/29/2019		Pending	Mexico
TAYYS-012/02NZ	FEEDBACK ENABLED SYNTHETIC GENES, TARGET SEED MATCH CASSETTES, AND THEIR USES	773166 8/29/2019		Pending	New Zealand
TAYYS-012/02RU	FEEDBACK ENABLED SYNTHETIC GENES, TARGET SEED MATCH CASSETTES, AND THEIR USES	2021107929 8/29/2019		Abandoned	Russian Federation
TAYYS-012/02SG	FEEDBACK ENABLED SYNTHETIC GENES, TARGET SEED MATCH CASSETTES, AND THEIR USES	11202102013X 8/29/2019		Pending	Singapore
TAYYS-012/02US	FEEDBACK ENABLED SYNTHETIC GENES, TARGET SEED MATCH CASSETTES, AND THEIR USES	177271,432 8/29/2019		Pending	United States of America
TAYYS-013 – Transgene: Anti-Mouse IgG1 – Indication: Tauopathies (TSHA-113) Assignee: The Board of Regents of the University of Texas System					
TAYYS-013/P01US	TAU REDUCTION GENE THERAPY	63/215,833 6/28/2021		Expired	United States of America
TAYYS-013/P02US	TAU REDUCTION GENE THERAPY	63/267,440 2/2/2022		Expired	United States of America
TAYYS-013/P03US	METHODS AND COMPOSITIONS FOR TAU REDUCTION GENE THERAPY	63/342,240 5/16/2022		Expired	United States of America

TAYS-013/001WO	METHODS AND COMPOSITIONS FOR TAU REDUCTION GENE THERAPY	PCT/US2022/035091	6/27/2022	Pending	Patent Cooperation Treaty
TAYS-014 - Transgene: <i>CLN1</i> - Indication: <i>CLN1 Disease/Infantile Batten Disease (TSHA-118)</i> Assignee: The University of North Carolina at Chapel Hill					
TAYS-014/P01US	INTRATHECAL AND INTRAVENOUS COMBINATION GENE THERAPY FOR THE TREATMENT OF INFANTILE BATTEN DISEASE	62/840,360	4/29/2019	Expired	United States of America
TAYS-014/01WO	INTRATHECAL AND INTRAVENOUS COMBINATION GENE THERAPY FOR THE TREATMENT OF INFANTILE BATTEN DISEASE	PCT/US2020/030427	4/29/2020	Expired/PCT Period Over	Patent Cooperation Treaty
TAYS-014/01AU	INTRATHECAL AND INTRAVENOUS COMBINATION GENE THERAPY FOR THE TREATMENT OF INFANTILE BATTEN DISEASE	2020264438	4/29/2020	Pending	Australia
TAYS-014/N01BR	INTRATHECAL AND INTRAVENOUS COMBINATION GENE THERAPY FOR THE TREATMENT OF INFANTILE BATTEN DISEASE	BR112021021632-4	4/29/2020	Abandoned	Brazil
TAYS-014/N01CA	INTRATHECAL AND INTRAVENOUS COMBINATION GENE THERAPY FOR THE TREATMENT OF INFANTILE BATTEN DISEASE	3138274	4/29/2020	Abandoned	Canada
TAYS-014/N01CN	INTRATHECAL AND INTRAVENOUS COMBINATION GENE THERAPY FOR THE TREATMENT OF INFANTILE BATTEN DISEASE	20208087719.4	4/29/2020	Abandoned	China
TAYS-014/01EP	INTRATHECAL AND INTRAVENOUS COMBINATION GENE THERAPY FOR THE TREATMENT OF INFANTILE BATTEN DISEASE	20798198.6	4/29/2020	Pending	European Patent Office
TAYS-014/N01IL	INTRATHECAL AND INTRAVENOUS COMBINATION GENE THERAPY FOR THE TREATMENT OF INFANTILE BATTEN DISEASE	287608	4/29/2020	Pending	Israel
TAYS-014/N01IN	INTRATHECAL AND INTRAVENOUS COMBINATION GENE THERAPY FOR THE TREATMENT OF INFANTILE BATTEN DISEASE	202127052580	4/29/2020	Abandoned	India
TAYS-014/N01JP	INTRATHECAL AND INTRAVENOUS COMBINATION GENE THERAPY FOR THE TREATMENT OF INFANTILE BATTEN DISEASE	2021-564486	4/29/2020	Pending	Japan
TAYS-014/N01KR	INTRATHECAL AND INTRAVENOUS COMBINATION GENE THERAPY FOR THE TREATMENT OF INFANTILE BATTEN DISEASE	10-2021-7038864	4/29/2020	Abandoned	Republic of Korea
TAYS-014/N01MX	INTRATHECAL AND INTRAVENOUS COMBINATION GENE THERAPY FOR THE TREATMENT OF INFANTILE BATTEN DISEASE	MX/a/2021/013275	4/29/2020	Pending	Mexico
TAYS-014/N01NZ	INTRATHECAL AND INTRAVENOUS COMBINATION GENE THERAPY FOR THE TREATMENT OF INFANTILE BATTEN DISEASE	782434	4/29/2020	Pending	New Zealand

TAYS-014/N01RU	INTRATHECAL AND INTRAVENOUS COMBINATION GENE THERAPY FOR THE TREATMENT OF INFANTILE BATTEN DISEASE	2021134508 4/29/2020	Abandoned	Russian Federation
TAYS-014/N01SG	INTRATHECAL AND INTRAVENOUS COMBINATION GENE THERAPY FOR THE TREATMENT OF INFANTILE BATTEN DISEASE	11202111908X 4/29/2020	Abandoned	Singapore
TAYS-014/N01US	INTRATHECAL AND INTRAVENOUS COMBINATION GENE THERAPY FOR THE TREATMENT OF INFANTILE BATTEN DISEASE	17/607,315 4/29/2020	Pending	United States of America
TAYS-014/01ZA	INTRATHECAL AND INTRAVENOUS COMBINATION GENE THERAPY FOR THE TREATMENT OF INFANTILE BATTEN DISEASE	2021/08424 4/29/2020	Abandoned	South Africa
TAYS-015 – Transgene: SL/C13A5 – Indication: SL/C13A5 Deficiency (TSHA-105)				
Assignee: The Board of Regents of the University of Texas System				
TAYS-015/P01US	SL/C13A5 GENE THERAPY VECTORS AND USES THEREOF	63/250,761 9/30/2021	Expired	United States of America
TAYS-015/P02US	SL/C13A5 GENE THERAPY VECTORS AND USES THEREOF	63/364,655 5/13/2022	Expired	United States of America
TAYS-015/001WO	SL/C13A5 GENE THERAPY VECTORS AND USES THEREOF	PCT/US2022/077224 9/29/2022	Pending	Patent Cooperation Treaty
TAYS-016 – Transgene: UBE3A – Indication: Angelman Syndrome (TSHA-106)				
Assignee: The University of North Carolina at Chapel Hill				
TAYS-016/P01US	UBE3A GENES AND EXPRESSION CASSETTES AND THEIR USE	62/851,411 5/22/2019	Expired	United States of America
TAYS-016/001WO	UBE3A GENES AND EXPRESSION CASSETTES AND THEIR USE	PCT/US2020/034171 5/22/2020	Expired/PCT Period Over	Patent Cooperation Treaty
TAYS-016/N01AU	UBE3A GENES AND EXPRESSION CASSETTES AND THEIR USE	3020279387 5/22/2020	Pending	Australia
TAYS-016/N01CA	UBE3A GENES AND EXPRESSION CASSETTES AND THEIR USE	3139678 5/22/2020	Abandoned	Canada
TAYS-016/N01CN	UBE3A GENES AND EXPRESSION CASSETTES AND THEIR USE	202080050918.0 5/22/2020	Pending	China
TAYS-016/N01EA	UBE3A GENES AND EXPRESSION CASSETTES AND THEIR USE	202193214 5/22/2020	Pending	Eurasian Patent Organization
TAYS-016/N01EP	UBE3A GENES AND EXPRESSION CASSETTES AND THEIR USE	20809370.8 5/22/2020	Pending	European Patent Office
TAYS-016/N01IL	UBE3A GENES AND EXPRESSION CASSETTES AND THEIR USE	287943 5/22/2020	Pending	Israel
TAYS-016/N01JP	UBE3A GENES AND EXPRESSION CASSETTES AND THEIR USE	2021-569494 5/22/2020	Pending	Japan
TAYS-016/N01KR	UBE3A GENES AND EXPRESSION CASSETTES AND THEIR USE	10-2021-7041626 5/22/2020	Pending	Republic of Korea
TAYS-016/N01MX	UBE3A GENES AND EXPRESSION CASSETTES AND THEIR USE	MX/A/2021/014248 5/22/2020	Pending	Mexico

TAYS-016/N01SG	UBE3A GENES AND EXPRESSION CASSETTES AND THEIR USE	11202112470Y		Pending	Singapore
TAYS-016/N01US	UBE3A GENES AND EXPRESSION CASSETTES AND THEIR USE	17/612.833	5/22/2020	Pending	United States of America
TAYS-016/N01ZA	UBE3A GENES AND EXPRESSION CASSETTES AND THEIR USE	2021/09006	5/22/2020	Pending	South Africa
TAYS-017 – Transgene: Anti- <i>EHMT2</i> RNAi – Indication: Prader-Willi Syndrome (TSHA-116) Assignee: The Board of Regents of the University of Texas System					
TAYS-017/P01US	GENE THERAPY FOR PRADER WILLI SYNDROME	63/274.723	11/2/2021	Expired	United States of America
TAYS-017/001WO	GENE THERAPY FOR PRADER WILLI SYNDROME	PCT/US2022/079117	10/31/2022	Pending	Patent Cooperation Treaty
TAYS-018 – Transgene: Anti- <i>GYS1</i> RNAi – Indication: Adult polyglucosan body disease (TSHA-112) and Lafora Disease (TSHA-111) Assignee: The Board of Regents of the University of Texas System					
TAYS-018/P01US	RNAI THERAPY FOR APBD AND LAFORA DISEASE	63/281.336	11/19/2021	Expired	United States of America
TAYS-018/001WO	RNAI THERAPY FOR APBD AND LAFORA DISEASE	PCT/US2022/080028	11/17/2022	Pending	Patent Cooperation Treaty
TAYS-019 – Transgene: <i>SLC13A5</i> Deficiency (TSHA-105) Assignee: The University of North Carolina at Chapel Hill					
TAYS-019/001WO	OPTIMIZED SLC13A5 GENES AND EXPRESSION CASSETTES AND THEIR USE	PCT/US2022/042930	7/23/2021	Expired/PCT Period Over	Patent Cooperation Treaty
TAYS-019/N01CA	OPTIMIZED SLC13A5 GENES AND EXPRESSION CASSETTES AND THEIR USE	3186207	7/23/2021	Pending	Canada
TAYS-019/N01EP	OPTIMIZED SLC13A5 GENES AND EXPRESSION CASSETTES AND THEIR USE	21845857.8	7/23/2021	Pending	European Patent Office
TAYS-019/N01JP	OPTIMIZED SLC13A5 GENES AND EXPRESSION CASSETTES AND THEIR USE	2023-503171	7/23/2021	Pending	Japan
TAYS-019/N01US	OPTIMIZED SLC13A5 GENES AND EXPRESSION CASSETTES AND THEIR USE	18/006.278	7/23/2021	Pending	United States of America
TAYS-020 – Transgene: <i>Her1</i> / <i>Hes1</i> – Indication: GM2 Gangliosides (TSHA-101) Assignee: Queen's University at Kingston and Kingston Health Sciences Centre					
TAYS-020/P01US	METHODS AND GENES THERAPY CONSTRUCTS FOR TREATING GM2 GANGLIOSIDOSIS	62/348.003	6/9/2016	Expired	United States of America
TAYS-020/001US	METHODS AND GENE THERAPY CONSTRUCTS FOR TREATING GM2 GANGLIOSIDOSIS	15/617.465	6/8/2017	Registered	United States of America
TAYS-020/C01US	METHODS AND GENE THERAPY CONSTRUCTS FOR TREATING GM2 GANGLIOSIDOSIS	17/325.417	5/20/2021	Allowed	United States of America
TAYS-021 – Transgene: <i>SUMF1</i> – Indication: Multiple Sulfatase Deficiency Assignee: The University of North Carolina at Chapel Hill					
TAYS-021/P01US	OPTIMIZED SUMF1 GENES AND EXPRESSION CASSETTES AND THEIR USE	62/840.114	4/29/2019	Expired	United States of America
TAYS-021/001WO	OPTIMIZED SUMF1 GENES AND EXPRESSION CASSETTES AND THEIR USE	PCT/US2020/030236	4/28/2020	Expired/PCT Period Over	Patent Cooperation Treaty

TAYS-021/N01CA	OPTIMIZED SUMF1 GENES AND EXPRESSION CASSETTES AND THEIR USE	3144654	4/28/2020		Pending	Canada
TAYS-021/N01EP	OPTIMIZED SUMF1 GENES AND EXPRESSION CASSETTES AND THEIR USE	20798551.6	4/28/2020		License terminated	European Patent Office
TAYS-021/N01US	OPTIMIZED SUMF1 GENES AND EXPRESSION CASSETTES AND THEIR USE	17/606,890	4/28/2020		Pending	United States of America
TAYS-023 - Transgene: <i>GNAO1</i> - Indication: <i>GNAO1</i> -related epilepsies Assignee: The Board of Regents of the University of Texas System						
TAYS-023/P01US	GNAO1 GENE THERAPY VECTORS AND USES THEREOF	63/285,682	12/3/2021		Expired	United States of America
TAYS-023/001WO	GNAO1 GENE THERAPY VECTORS AND USES THEREOF	PCT/US2022/080805	12/2/2022		Pending	Patent Cooperation Treaty
TAYS-024 - Transgene: <i>CLN7</i> - Indication: Batten Disease (TSHA-118) Assignee: The Board of Regents of the University of Texas System						
TAYS-024/P01US	VECTOR GENOME DESIGN TO EXPRESS OPTIMIZED <i>CLN7</i> TRANSGENE	63/284,852	12/1/2021		Expired	United States of America
TAYS-024/001WO	VECTOR GENOME DESIGN TO EXPRESS OPTIMIZED <i>CLN7</i> TRANSGENE	PCT/US2022/080625	11/30/2022		Pending	Patent Cooperation Treaty
TAYS-025 - Transgene: <i>FMRI</i> - Indication: Fragile X Disorder Assignee: The Board of Regents of the University of Texas System						
TAYS-025/P01US	TRANSGENE CASSETTE DESIGNED TO EXPRESS THE HUMAN CODON-OPTIMIZED GENE <i>FMRI</i>	63/267,236	1/28/2022		Expired	United States of America
TAYS-025/001WO	TRANSGENE CASSETTE DESIGNED TO EXPRESS THE HUMAN CODON-OPTIMIZED GENE <i>FMRI</i>	PCT/US2023/061433	1/27/2023		Pending	Patent Cooperation Treaty
TAYS-027 - Transgene: <i>PTEN</i> - Indication: <i>PTEN</i> -related disorders (cancer) Assignee: The Board of Regents of the University of Texas System						
TAYS-027/P01US	<i>PTEN</i> GENE THERAPY VECTORS AND USES THEREOF	63/441,925	1/30/2023		Pending	United States of America

EXHIBIT C

TRADEMARKS

See attached.

COPY VIEW

Host File Number	Mark / Title	Country	Country Name	Type	Date filed	Application Number	Registration Date	Registration Number	Trademark Class Code	Class Code / Description	Status
5945.0002-000	TAVSHA GENE THERAPIES	US	United States of America	Trademark	Jun 15, 2021	90/773,805			005	005-Pharmaceuticals and pharmaceutical preparations for use in the treatment of genetic diseases and disorders	Allowed
5945.0002-001	TAVSHA GENE THERAPIES	IB	International Bureau (WIPO)	Trademark	Nov 9, 2021	A0115955	Nov 9, 2021	1631366	005	005-Pharmaceuticals and pharmaceutical preparations for use in the treatment of genetic diseases and disorders	Registered
5945.0002-002	TAVSHA GENE THERAPIES	AU	Australia	Trademark	Nov 9, 2021	A0115955	Nov 9, 2021	1631366	005	005-Pharmaceuticals and pharmaceutical preparations for use in the treatment of genetic diseases and disorders	Registered
5945.0002-003	TAVSHA GENE THERAPIES	CA	Canada	Trademark	Nov 9, 2021	A0115955			005	005-Pharmaceuticals and pharmaceutical preparations for use in the treatment of genetic diseases and disorders	Pending
5945.0002-004	TAVSHA GENE THERAPIES	CN	China	Trademark	Nov 9, 2021	A0115955	Nov 9, 2021	1631366	005	005-Pharmaceuticals and pharmaceutical preparations for use in the treatment of genetic diseases and disorders	Registered
5945.0002-005	TAVSHA GENE THERAPIES	EM	European Union	Trademark	Nov 9, 2021	A0115955	Nov 9, 2021	1631366	005	005-Pharmaceuticals and pharmaceutical preparations for use in the treatment of genetic diseases and disorders	Registered
5945.0002-006	TAVSHA GENE THERAPIES	IN	India	Trademark	Nov 9, 2021	A0115955			005	005-Pharmaceuticals and pharmaceutical preparations for use in the treatment of genetic diseases and disorders	Abandoned
5945.0002-007	TAVSHA GENE THERAPIES	IL	Israel	Trademark	Nov 9, 2021	346562	Nov 9, 2021	1631366	005	005-Pharmaceuticals and pharmaceutical preparations for use in the treatment of genetic diseases and disorders	Registered
5945.0002-008	TAVSHA GENE THERAPIES	JP	Japan	Trademark	Nov 9, 2021	1631366	Nov 9, 2021	1631366	005	005-Pharmaceuticals and pharmaceutical preparations for use in the treatment of genetic diseases and disorders	Registered
5945.0002-009	TAVSHA GENE THERAPIES	MX	Mexico	Trademark	Nov 9, 2021	2669486			005	005-Pharmaceuticals and pharmaceutical preparations for use in the treatment of genetic diseases and disorders	Abandoned
5945.0002-010	TAVSHA GENE THERAPIES	NO	Norway	Trademark	Nov 9, 2021	A0115955			005	005-Pharmaceuticals and pharmaceutical preparations for use in the treatment of genetic diseases and disorders	Published
5945.0002-011	TAVSHA GENE THERAPIES	KR	Republic of Korea	Trademark	Nov 9, 2021	A0115955			005	005-Pharmaceuticals and pharmaceutical preparations for use in the treatment of genetic diseases and disorders	Pending

HBSR Trademark List

Host File Number	Mark / Title	Country	Country Name	Type	Date filed	Application Number	Registration Date	Registration Number	Trademark Class Code	Class Code / Description	Status
5945.0002-012	TAVSHA GENE THERAPIES	RU	Russian Federation	Trademark	Nov 9, 2021	A0115955			005	005-Pharmaceuticals and pharmaceutical preparations for use in the treatment of genetic diseases and disorders	Abandoned
5945.0002-013	TAVSHA GENE THERAPIES	SG	Singapore	Trademark	Nov 9, 2021	A0115955			005	005-Pharmaceuticals and pharmaceutical preparations for use in the treatment of genetic diseases and disorders	Published
5945.0002-014	TAVSHA GENE THERAPIES	CH	Switzerland	Trademark	Nov 9, 2021	A0115955			005	005-Pharmaceuticals and pharmaceutical preparations for use in the treatment of genetic diseases and disorders	Pending
5945.0002-015	TAVSHA GENE THERAPIES	GB	United Kingdom	Trademark	Nov 9, 2021	A0115955	Nov 9, 2021	1631366	005	005-Pharmaceuticals and pharmaceutical preparations for use in the treatment of genetic diseases and disorders	Registered

TRADEMARK
REEL: 008257 FRAME: 0574

THIS IS A COPY
This is a copy view of the Authoritative Copy held
by the designated custodian

COOPY
NEW

EXHIBIT D

MASK WORKS

None.

COPY VIEW